LAUSR

We have read with great interest the recently published paper by Martinelli et al. about poor immunization status of children with the diagnosis of Inflammatory Bowel Disease (IBD) and about insufficient serological testing before starting biological therapy (1). The use of immunomodulators and biological therapy is associated with increased risk of opportunistic infections and the flare-ups of latent infections. With the increased use of these therapies, altered immunological status challenges physicians during the management of patients with IBD.